Page 21 - 2023-02-中国全科医学
P. 21

·142·  http: //www.chinagp.net   E-mail: zgqkyx@chinagp.net.cn                     January  2023, Vol.26  No.2


                                                                                      ·指南·循证·


           完全血运重建治疗急性心肌梗死合并多支血管病变效果

           的系统评价再评价

                                                                                                   扫描二维码
                                              2
                           3
                                    4
           王哲  1,2 ,赵海滨 ,汪国梁 ,马晓娟 ,殷惠军                 2*                                           查看原文
               【摘要】 背景 对于急性心肌梗死合并多支血管病变的治疗,目前主要有单纯罪犯血管血运重建及完全血运
           重建两种方法,虽然许多系统评价对比了这两种治疗方法的有效性和安全性,但其质量和结果不尽相同,无法直接
           应用于临床。目的 对完全血运重建治疗急性心肌梗死合并多支血管病变的效果进行系统评价再评价。方法 检索
           PubMed、Cochrane Library 和 Embase 及 PROSPERO 数据库,搜集对比完全血运重建和单纯罪犯血管血运重建治疗急性
           心肌梗死合并多支血管病变效果的系统评价或 Meta 分析,检索时限为建库至 2022 年 2 月,无语言及发表状态限制。
           由 2 名研究者使用 AMSTAR 2 量表、GRADE 分级系统分别评价其方法学质量和证据质量。结果 共纳入 25 篇符合条
           件的系统评价 /Meta 分析。根据 AMSTAR 2 量表评价结果,纳入研究的方法学质量整体偏低,1 篇为高质量,2 篇为中
           质量,22 篇为极低质量。25 篇文献共涉及 8 个结局指标,135 个证据体,其中 8 个 GRADE 分级为高级,17 个为中级,
           其余为低级或极低级。结论 相较单纯罪犯血管血运重建,完全血运重建可以改善急性心肌梗死合并多支血管病变患
           者的部分临床结局,但其安全性有待大样本、高质量临床研究的进一步评估。
               【关键词】 心肌梗死;完全血运重建;罪犯血管血运重建;系统评价;主要不良心血管事件;心血管疾病
               【中图分类号】 R 542.22 【文献标识码】 A DOI:10.12114/j.issn.1007-9572.2022.0428
               王哲,赵海滨,汪国梁,等 . 完全血运重建治疗急性心肌梗死合并多支血管病变效果的系统评价再评价[J]. 中
           国全科医学,2023,26(2):142-153.[www.chinagp.net]
               WANG Z,ZHAO H B,WANG G L,et al. Complete revascularization for acute myocardial infarction and multivessel
           disease:an overview of systematic reviews[J]. Chinese General Practice,2023,26(2):142-153.

           Complete Revascularization for Acute Myocardial Infarction and Multivessel Disease:an Overview of Systematic
                                                      4
                                        3
                                                                  2
           Reviews WANG Zhe 1,2 ,ZHAO Haibin ,WANG Guoliang ,MA Xiaojuan ,YIN Huijun 2*
           1.Graduate School,Beijing University of Chinese Medicine,Beijing 100105,China
           2.Cardiovascular Center,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing 100091,China
           3.Department of Cardiology,Dongfang Hospital,Beijing University of Chinese Medicine,Beijing 100078,China
           4.Department of Traditional Chinese Medicine,Shaoxing People's Hospital,Shaoxing 312099,China
           *
           Corresponding author:YIN Huijun,Chief physician;E-mail:huijunyin@yeah.net
               【Abstract】 Background Culprit-only revascularization and complete revascularization are two major treatments for
           acute myocardial infarction(AMI) with multivessel disease. Many systematic reviews have compared the efficacy and safety
           of the two treatments,but the review results are inconsistent and cannot be directly applied to clinical practice. Objective
            To perform an overview of the systematic reviews of the efficacy and safety of complete revascularization versus culprit-
           only revascularization for AMI with multivessel disease. Methods PubMed,Cochrane Library,Embase and PROSPERO
           databases were searched from inception to February,2022 for systematic reviews/meta-analyses about complete revascularization
           versus culprit-only revascularization for AMI with multivessel disease regardless of the language and status of publication. Two
           researchers independently evaluated the methodological quality and evidence quality of included studies using the AMSTAR 2 and
           GRADE,respectively. Results A total of 25 systematic reviews or meta-analyses were included. The methodological quality of
           the included studies was generally low,with one being of high quality,two being of moderate quality,and 22 being of critical


               基金项目:国家自然科学基金资助项目(82074418)
               本研究 PROSPERO 注册号:CRD42022309044
               1.100105 北京市,北京中医药大学研究生院 2.100091 北京市,中国中医科学院西苑医院心血管病中心 3.100078 北京市,北
           京中医药大学东方医院心血管科 4.312099 浙江省绍兴市人民医院中医科
               *  通信作者:殷惠军,主任医师;E-mail:huijunyin@yeah.net
               本文数字出版日期:2022-10-27
   16   17   18   19   20   21   22   23   24   25   26